Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera by de Alwis, Ruklanthi et al.
Dengue Viruses Are Enhanced by Distinct Populations of
Serotype Cross-Reactive Antibodies in Human Immune
Sera
Ruklanthi de Alwis1, Katherine L. Williams2, Michael A. Schmid2, Chih-Yun Lai3, Bhumi Patel1,
Scott A. Smith4, James E. Crowe4, Wei-Kung Wang3, Eva Harris2*, Aravinda M. de Silva1*
1 Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States of America,
2 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America, 3 Department of
Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America, 4 Departments of Medicine,
Pediatrics, Pathology, Microbiology and Immunology, and The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville,
Tennessee, United States of America
Abstract
Dengue viruses (DENV) are mosquito-borne flaviviruses of global importance. DENV exist as four serotypes, DENV1-DENV4.
Following a primary infection, individuals produce DENV-specific antibodies that bind only to the serotype of infection and
other antibodies that cross-react with two or more serotypes. People exposed to a secondary DENV infection with another
serotype are at greater risk of developing more severe forms of dengue disease. The increased risk of severe dengue in
people experiencing repeat DENV infections appear to be due, at least in part, to the ability of pre-existing serotype cross-
reactive antibodies to form virus-antibody complexes that can productively infect Fcc receptor-bearing target cells. While
the theory of antibody-dependent enhancement (ADE) is supported by several human and small animal model studies, the
specific viral antigens and epitopes recognized by enhancing human antibodies after natural infections have not been fully
defined. We used antibody-depletion techniques to remove DENV-specific antibody sub-populations from primary DENV-
immune human sera. The effects of removing specific antibody populations on ADE were tested both in vitro using K562
cells and in vivo using the AG129 mouse model. Removal of serotype cross-reactive antibodies ablated enhancement of
heterotypic virus infection in vitro and antibody-enhanced mortality in vivo. Further depletion studies using recombinant
viral antigens showed that although the removal of DENV E-specific antibodies using recombinant E (rE) protein resulted in
a partial reduction in DENV enhancement, there was a significant residual enhancement remaining. Competition ADE
studies using prM-specific Fab fragments in human immune sera showed that both rE-specific and prM-specific antibodies
in primary DENV-immune sera significantly contribute to enhancement of heterotypic DENV infection in vitro. Identification
of the targets of DENV-enhancing antibodies should contribute to the development of safe, non-enhancing vaccines against
dengue.
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Introduction
Dengue is present in over 100 countries and is the most
common arthropod-borne viral disease of humans [1,2]. Dengue
disease is caused by dengue virus (DENV), which exists as four
closely-related serotypes (DENV1-DENV4). DENV spreads be-
tween humans through the mosquito vectors Aedes aegypti and
Aedes albopictus. Recent studies estimate that approximately 390
million individuals are infected with DENV globally each year,
causing around 100 million clinically apparent cases [3]. There are
currently no approved therapeutics or vaccines against DENV.
Primary DENV infections in humans result in type-specific as
well as serotype cross-reactive antibodies. However, life-long
protective immunity is only directed against the serotype of
infection. During a secondary infection with another DENV
serotype, individuals are at a greater risk of severe disease than
during a primary infection [4–6]. Furthermore, in DENV-
endemic regions, infants between the ages of 6 and 12 months
are also a high-risk group for severe forms of dengue disease [7–9].
One of the most compelling explanations for the higher
proportions of severe disease in infants and secondary heterotypic
DENV infections is the phenomenon of antibody-dependent
enhancement (ADE) [4–6]. ADE of DENV infection is expected to
occur when pre-existing sub-neutralizing antibodies (e.g., from a
primary infection) bind to a heterotypic virus during a subsequent
infection and facilitate the entry of the virus through Fcc receptor
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(FccR)-mediated endocytosis into myeloid cells (such as monocytes
and macrophages). Through mechanisms that are largely unclear,
the antibody-bound virus escapes the phagolysosome and estab-
lishes a productive infection within the host cell [10]. Furthermore,
productive DENV infections through ADE (as compared to the
conventional route of entry) have been found to result in higher
viremia and a suppressed host antiviral state [11–19].
Development of a suitable small animal model for the
investigation of DENV infection and antibody responses has been
hindered by the low or lack of DENV replication in immuno-
competent mouse models. The first mouse models consisted of
intracranial DENV challenges in immunocompetent suckling
mice. However, these models resulted in death through neurolog-
ical disease and paralysis, which are rarely seen in human dengue
[20,21]. DENV replication in a rodent model was first shown in
the IFN-a/b and -c receptor-deficient AG129 mouse model [22].
It was further demonstrated that the AG129 mouse model also
presents a lethal vascular leakage syndrome with features similar to
human disease when challenged with a high dose of DENV or a
sub-lethal dose of DENV in the presence of DENV-specific
enhancing antibodies [23–25]. Therefore, AG129 mice presently
constitute the most suitable animal model available for testing
antibodies for enhancement of DENV infections.
Recent studies investigating the memory B cell response after
natural DENV infections have revealed that the antibody response
in humans is dominated by cross-reactive, weakly neutralizing
antibodies [26–29]. These cross-reactive antibodies were found to
efficiently enhance DENV infection, usually over a wide range of
concentrations [26–29]. A study analyzing the memory B cell
response in humans after immunization with a monovalent
formulation of a leading DENV vaccine candidate observed a
similar dominantly cross-reactive, weakly neutralizing antibody
response [30].
The specific antigens and epitopes on the virion targeted by
enhancing antibodies in human immune sera have not been well
defined. Nearly all DENV-specific antibodies, regardless of
neutralization potency, will at some concentration enhance
infection in FccR-bearing cells. Thus, to investigate the viral
epitopes targeted by antibodies responsible for enhancement of
secondary DENV infection, it is insufficient to analyze enhance-
ment properties of isolated human monoclonal antibodies (MAbs).
Rather, the antibody repertoire in circulation prior to secondary
infection needs to be examined, and ADE assays must be
performed at antibody concentrations that approximate physio-
logical concentrations in circulation or at the very least at low
dilutions. The present study investigates the properties of
antibodies in people exposed to primary infections that are
responsible for enhancement of heterotypic DENV serotypes. The
studies are conducted both in vitro (using the FccR-bearing cell
line, K562) and in vivo (using the AG129 mouse model). We
demonstrate that primary DENV-immune human sera have
distinct populations of antibodies that are responsible for DENV
neutralization and ADE. The enhancing antibodies bind to
serotype cross-reactive epitopes on envelope (E) and prM antigens
on the viral surface.
Results
People exposed to primary DENV infections develop a
dominant serotype cross-reactive antibody response and a minor
population of antibodies that are specific to the serotype of
infection [31]. Previously, we demonstrated that the type-specific,
and not the cross-reactive, antibodies were responsible for the
ability of late convalescent primary DENV-immune sera to
neutralize DENV [31]. Here we began by performing experiments
to determine whether the dominant cross-reactive antibody
response was responsible for ADE of DENV in both K562 cells
and the AG129 mouse model.
We used the human erythromyeloblastoid leukemia cell line,
K562, for investigation of enhancing antibodies in DENV-
immune human sera. These cells, which express FccRIIa, are
only permissive to DENV infection in the presence of enhancing
antibodies. At high serum concentrations (i.e., 1:40 in Figure 1A
and B), both primary DENV2- and DENV3-immune human sera
enhanced heterotypic serotypes, but not the respective homotypic
serotypes in vitro. Similarly, DENV-immune human sera were
tested in the AG129 mouse model of antibody-enhanced dengue
disease. The AG129 mice were passively administered human
DENV-immune sera 24 hours prior to infection with the DENV2
strain D2S10 (Figure 1C). The homotypic immune human sera
(i.e., primary DENV2-immune) did not induce any illness (data
not shown) or death (Figure 1D) in mice challenged with a
sublethal dose of DENV2, whereas passive transfer of the same
quantity of heterotypic human serum (i.e., primary DENV1,
DENV3 or DENV4-immune sera) led to significant ADE-induced
disease (data not shown) and mortality (DENV-naı̈ve human
serum (NHS) compared to aDENV1, p = 0.0007; aDENV3,
p,0.0001; aDENV4, p,0.0001).
Depletion of Cross-Reactive Antibodies Ablates ADE of
Heterotypic DENV
Next, we used in vitro and in vivo models to identify specific
antibody populations in polyclonal sera that drive ADE. Primary
DENV2-immune sera were depleted with the heterotypic virus
DENV3, and primary DENV3-immune human sera were
depleted with the heterotypic virus DENV2. As shown in
Figure 2A and Figure 3A, successful virus-specific depletion
was confirmed using a virus-binding ELISA. When primary
DENV2-immune serum was depleted with DENV3 (Figure 2A),
all cross-reactive binding antibodies were removed, and when
primary DENV3-immune serum was depleted with DENV2, the
remaining antibody bound to DENV3 and to a lesser extent to
Author Summary
The mosquito-borne dengue viruses (DENV) are responsi-
ble for approximately 390 million new infections world-
wide each year, and an estimated 100 million of these
infections lead to clinical disease. The presence of four
different serotypes of DENV allows the same individual to
experience more than one DENV infection. Secondary
DENV infections with a different serotype are more likely to
cause severe dengue disease than primary infections. One
of the explanations for the greater risk of severe disease
during secondary DENV infections is the phenomenon
called antibody-dependent enhancement (ADE), where
pre-existing DENV-specific antibodies enable entry of
DENV into target host cells, and thereby enhance infection
and disease. At the moment, the epitopes targeted by
enhancing antibodies following a DENV infection are
unclear. In the present study, we use novel techniques
to fractionate human serum antibodies and test their
ability to enhance DENV infection both in vitro (K562 cells)
and in vivo (in a mouse model of lethal antibody-enhanced
dengue disease). We found that antibodies binding both
the envelope and prM proteins on the DENV virion play an
important role in ADE of DENV by human immune sera.
Our findings about DENV-enhancing antibodies in human
immune sera are relevant to developing safe vaccines.
Human Antibody Enhancement of Dengue Virus
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DENV1 (Figure 3A). This latter observation is consistent with
known antigenic relationships between DENV serotypes; DENV1
and DENV3 share common epitopes that are not present in
DENV2 or DENV4. In vitro ADE studies with heterotypic-virus
depleted sera showed that removal of DENV3 virus-binding
antibodies from primary DENV2-immune human sera completely
ablated enhancement of the heterotypic serotypes, DENV1,
DENV3 and DENV4 (Figure 2B, D and E), demonstrating
that cross-reactive antibodies are responsible for enhancement of
heterotypic serotypes. However, peak enhancement of the
homotypic serotype, DENV2, was not affected by the removal
of cross-reactive antibodies from DENV2-immune sera (Fig-
ure 2C), which suggests that homotypic enhancement only occurs
when type-specific antibodies are diluted to low concentrations.
Similar results were observed for primary DENV3-immune sera,
where depletion of DENV2-specific antibodies completely re-
moved all enhancement of infection by the heterotypic serotypes,
DENV1, DENV2 and DENV4 (Figure 3B, C, and E), but not
by the homotypic serotype DENV3 when diluted to low
concentrations (Figure 3D).
DENV-immune sera depleted of all cross-reactive antibodies
were then transferred into AG129 mice to assess the role of cross-
reactive antibodies in DENV enhancement in vivo. Passive
administration of control-depleted, primary DENV3-immune sera
into AG129 mice prior to infection with a sublethal dose of
DENV2 D2S10 resulted in 100% mortality via ADE (Figure 4).
However, removal of heterotypic virus-binding antibodies from
primary DENV3-immune sera (by depleting with DENV2) led to
100% survival (p,0.0001 comparing groups administered
DENV2 virion- or control-depleted sera), similar to mice
administered virion- or control-depleted DENV-naı̈ve human
sera (Figure 4). Thus, cross-reactive antibodies binding to the
virion (i.e., the structural proteins) are the main antibody
component in human immune serum responsible for heterotypic
DENV enhancement both in cell culture and in the ADE mouse
model.
Depletion of Recombinant E-Specific Antibodies
Decreases ADE of Heterotypic DENV
We next investigated the role of DENV E protein-binding
antibodies in heterotypic DENV enhancement. Primary DENV-
immune human sera were depleted of cross-reactive E-binding
antibodies using heterotypic purified recombinant DENV E
protein (rE). Removal of cross-reactive rE-binding antibodies
from primary DENV3-immune serum eliminated binding to the
homotypic DENV3 rE protein as well, indicating that a majority
Figure 1. Primary DENV-immune human sera enhance heterotypic but not homotypic serotypes at high serum concentrations in
vitro and in vivo. (A and B) Enhancement of heterotypic and homotypic DENV by primary DENV2-immune (DT 001) (A) and DENV3-immune
(DT118) (B) sera at high serum concentration (1:40) in K562 cells. Data are representative of 8 serum samples. C) Human serum was passively
transferred to AG129 mice 24 hours prior to administration of 26105 pfu of the DENV2 strain D2S10 and survival of the mice was assessed. D) ADE-
induced mortality in AG129 mice after D2S10 infection in the presence of heterotypic sera (primary DENV1, primary DENV3, and primary DENV4 sera)
and homotypic human serum (primary DENV2 serum). Statistics: in Figure 1A, ADE of DENV2 compared to DENV1, *p = 0.01; DENV3, **p,0.001; and
DENV4, ***p,0.0001; in Figure 1B, ADE of DENV3 compared to DENV1, *p = 0.02; DENV2, **p,0.005; and DENV4, ***p = 0.0003; in Figure 1D, NHS
compared to anti-DENV1 serum, ***p = 0.0007; anti-DENV3 serum, ****p,0.0001; anti-DENV4 serum, ****p,0.0001.
doi:10.1371/journal.ppat.1004386.g001
Human Antibody Enhancement of Dengue Virus
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of the antibodies binding this rE protein construct in DENV-
immune sera were cross-reactive (Figure 5A). The fusion loop
region in E protein domain II is a target of DENV cross-reactive
human antibodies. Using dengue virus-like-particles (VLP) with
mutations in the E protein fusion loop epitopes, we confirmed that
most fusion loop antibody was removed following rE depletion
Figure 2. Removal of cross-reactive antibodies from primary DENV2-immune sera, eliminates enhancement of heterotypic DENV
infection in vitro. A) DENV-binding ELISA shows that depletion of a primary DENV2-immune serum with DENV3 virus removes binding to
heterotypic DENV1, DENV3 and DENV4. (D–E) In ADE assays performed in K562 cells, depletion of cross-reactive antibodies from primary DENV2-
immune serum eliminated enhancement of heterotypic DENV1 (B), DENV3 (D), and DENV4 (E) but not homotypic DENV2 virus (C). Data are
representative of at least four different primary DENV2-immune human sera. *Significantly different by Students t-test with p,0.01, **DENV3-
depleted ADE curves significantly different from control-depleted ADE curves at serum dilutions 1:40, 1:80, 1:160 and 1:320 (Students t-test with p,
0.001).
doi:10.1371/journal.ppat.1004386.g002
Human Antibody Enhancement of Dengue Virus
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(Figure 5B). In vitro cell culture-based ADE investigations
showed that removal of cross-reactive DENV rE-binding antibod-
ies from DENV3-immune sera led to a partial decrease (i.e., a shift
of the curve to the right) in the enhancement potency of the
immune sera against heterotypic serotypes DENV1 and DENV2,
but not DENV4 (Figure 5C–F). Similar observations were seen
with rE-depleted DENV2-immune human sera against the
heterotypic DENV serotypes (data not shown). These results
Figure 3. Removal of cross-reactive antibodies from primary DENV3-immune human sera abolishes enhancement of heterotypic
DENV infection in vitro. A) DENV-binding ELISA shows that depletion of a primary DENV3-immune serum (DT118) with DENV2 virus removes
binding to heterotypic DENV2 and DENV4, while significantly reducing binding to heterotypic DENV1. (B–E) In ADE assays performed in K562 cells,
depletion of cross-reactive antibodies from primary DENV3-immune serum ablated enhancement of heterotypic DENV1 (B), DENV2 (C), and DENV4
(E), without reducing enhancement of homotypic DENV3 virus (D). Data are representative of at least four different primary DENV3-immune human
sera. *Significantly different by Students t-test with p,0.01, **DENV2-depleted ADE curves significantly different from control-depleted ADE curves at
serum dilutions 1:40, 1:80, 1:160 and 1:320 (Students t-test with p,0.001).
doi:10.1371/journal.ppat.1004386.g003
Human Antibody Enhancement of Dengue Virus
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indicate that rE-binding cross-reactive antibodies are at least
partially responsible for heterotypic enhancement.
The DENV enhancement properties of sera depleted of cross-
reactive, rE-binding antibodies were tested in vivo. Removal of
cross-reactive rE-binding antibodies resulted in survival of 40% of
the mice, which was significantly (p = 0.0098) different from mice
receiving the control-depleted sera where none of the animals
survived (Figure 6). However, the 40% survival following
depletion of cross-reactive rE-binding antibodies was also signif-
icantly (p = 0.0062) different from mice receiving the virion-
depleted a-DENV3 sera, where all the animals survived
(Figures 4 and 6). Similar results were observed for two different
primary DENV3-immune sera. Thus, DENV rE-binding cross-
reactive antibodies in primary DENV-immune human sera were
partially responsible for ADE of heterotypic DENV infections in
vivo as well.
Competition ADE Assays of Human DENV-Immune Sera
with prM-Binding Fab Fragments Indicate a Role for prM-
Binding Antibodies in ADE
Since we found that rE-binding antibodies were only partially
responsible for enhancement of heterotypic serotypes, we inves-
tigated the role of prM-binding antibodies in human immune sera.
prM is a small integral membrane protein that is difficult to
express and purify as a recombinant antigen. Thus, we probed the
importance of prM-binding antibodies by conducting competitive
ADE assays with primary DENV-immune sera and Fab fragments
from human MAbs that bound to prM. The competition ADE
assay was developed on the basis that at high concentrations, prM
Fab fragments, which cannot bind Fc receptors since they lack the
Fc portion of the antibody, should bind to DENV and prevent the
binding of potentially enhancing intact prM antibodies in serum.
Fab fragments were generated from the prM-binding MAbs 1B22
and 2K2 by proteolytic cleavage. Both MAbs 1B22 and 2K2 were
isolated from memory B cells following secondary DENV
infections (Table S1), and were mapped to prM by Western blot
and prM-binding ELISA (data not shown). As shown in
Figure 7A and Table S1, neither Fab 1B22 nor Fab 2K2
neutralized DENV1 at the concentrations used in the competitive
ADE assay. Enhancement of the heterotypic serotype, DENV1, by
primary DENV3-immune sera was not affected by the increasing
presence of a negative control binding Fab, 2D22 Fab (DENV2-
specific) (Figure 7B). However, addition of Fab 1B22 or Fab 2K2
competed for virus binding with DENV-specific antibodies in the
DENV3-immune serum and reduced enhancement of heterotypic
virus infection by 25–50% in a dose-dependent manner (Fig-
ure 7B). Thus, it appears that prM-binding antibodies in primary
immune serum also play a role in ADE of heterotypic DENV
serotypes.
Both E- and prM-Specific Antibodies Together Account
for a Majority of the Heterotypic ADE Observed In Vitro
We then utilized control-depleted and rE-antibody depleted
DENV-immune sera in the competition ADE assay to assess the
cumulative effect of both rE- and prM-specific antibodies to
enhancement of heterotypic DENV serotypes. As depicted in
Figure 7C and D, addition of prM Fab fragments to rE-depleted
primary DENV3-immune sera led to a complete loss of infection
enhancement of the heterotypic serotype, DENV1. As prM lies in
close proximity to the fusion loop on E protein, it is conceivable
that prM-binding Fab fragments not only block the binding of
other prM-specific antibodies, but also interfere with fusion loop-
binding antibodies. To test this possibility, we performed
competition-binding assays with prM Fab fragments and full-
length MAbs against fusion loop epitopes (Figure S1A and B),
EDIII epitopes (Figure S1C) and prM epitopes (Figure S1D).
While we observed strong competition between the anti-prM Fab
fragments and the full-length anti-prM MAb 2H2 (Figure S1D),
no competition was observed between anti-prM Fab fragments
and fusion loop-binding (Figure S1A and B) or EDIII-directed
MAbs (Figure S1C). Our results thus indicate that both fusion
loop and prM antibodies in human DENV-immune sera
independently contribute to ADE.
Discussion
On average, people exposed to secondary DENV infections
have a higher viremia and an increased risk of developing dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS) com-
pared to people experiencing primary infections [1,5]. ADE has
been proposed as an explanation for the increased risk of DHF/
Figure 4. Removal of cross-reactive antibodies from primary DENV3-immune sera significantly protects AG129 mice from ADE-
induced mortality. Primary DENV3-immune human sera (DT118 and DT105) were depleted with heterotypic DENV2 virus (resulting in depletion of
heterotypic anti-DENV1, DENV2 and DENV4 antibodies), transferred to AG129 mice 24 hours prior to administration of 26105 pfu DENV2 (D2S10),
and assessed for percent survival. ****Percent survival of virion-depleted DENV3 serum is significantly different from control-depleted DENV3 serum
(p,0.0001). Data are pooled from three independent experiments using two primary DENV3-immune human sera.
doi:10.1371/journal.ppat.1004386.g004
Human Antibody Enhancement of Dengue Virus
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DSS in infants born to DENV-immune mothers or in people
exposed to secondary DENV infections. The enhancement of
DENV infection by antibodies has been directly demonstrated in
cell culture and animal models of infection [12,17,23,25]. The
specific properties of antibodies in primary DENV-immune
human sera that are likely to enhance an infection with a new
serotype have not been definitively identified. Attempts to study
specific properties of enhancing antibodies has been complicated
by the observation that almost any DENV-specific antibody,
including strongly neutralizing antibodies, can enhance infection
Figure 5. DENV E-binding antibodies partially contribute to heterotypic virus-enhancing antibodies in vitro. A) Depleting primary
DENV3 serum (DT118) with rE of DENV1, DENV2 and DENV4 removed rE-binding antibodies as assessed by rE binding ELISA. B) The quantity of fusion
loop-specific antibodies in virus-depleted and rE-protein depleted sera was assessed using a virus-binding assay with wild-type and fusion loop-
mutated virus-like particles (*significantly different by Students t-test with p,0.02, ***p,0.001). UD: undetectable due to antibody concentration
being below the limit of detection. (C–F) In ADE assays performed with human K562 cells, removal of cross-reactive rE-specific antibodies from a
primary DENV3-immune human serum partially reduced enhancement of the heterotypic viruses DENV1 (B) and DENV2 (C), but not DENV4 (E) or the
homotypic virus, DENV3 (D). In panels C and D the DENV1-, 2-, and 4-depleted ADE curves were significantly different from control-depleted ADE
curves at serum dilutions 1:320, 1:640, and 1:1280 (Students t-test with p,0.05). Data are representative of four DENV-immune sera.
doi:10.1371/journal.ppat.1004386.g005
Human Antibody Enhancement of Dengue Virus
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at sub-neutralizing concentrations. The goal of the current study
was to use human immune sera at concentrations likely to exist in
people susceptible to secondary DENV infections and to define the
properties of enhancing antibodies in this polyclonal antibody
mixture.
Our results reported here, together with previous studies on
neutralizing antibodies, demonstrate that primary DENV-immune
sera consist of one population of type-specific antibodies that
neutralize the serotype (homotypic) of previous infection [31], and
a second population of serotype cross-reactive antibodies that
enhance new (heterotypic) serotypes. The envelope of DENV
contains E and prM proteins, and cross-reactive epitopes on both
these antigens are targeted by enhancing antibodies in human
sera. Our results indicate that prM- and E-specific antibodies each
contributed separately to ADE. Numerous DENV cross-reactive,
weakly neutralizing and strongly enhancing MAbs isolated from
both mice and human dengue cases have been mapped to the
highly conserved flavivirus fusion loop/peptide region at the tip of
domain II of E protein [32–35]. Our data support the idea that the
fusion loop is an important target of DENV-enhancing antibodies.
In addition to E-specific antibodies, several groups have recently
isolated many weakly neutralizing, cross-reactive prM-binding
antibodies from human PBMCs from individuals after natural
primary DENV infections [26–30]. Similar to MAbs 1B22 and
2K2 used in the present study, a majority of the isolated human
prM-specific MAbs have been mapped to the soluble, pr portion of
the prM protein [29,30,33,36,37]. This suggests that the soluble pr
portion may be the major target of human antibodies on the prM
protein. The X-ray crystallographic structure of the prM-E
heterodimer shows that the pr portion of prM sits directly above
the tip of EDII and partially covers the fusion loop of the E
protein, protecting it from premature fusion within the Golgi
apparatus [38]. In addition, detailed mapping analysis of these
prM antibodies has revealed epitopes on the pr protein that are in
close proximity to the fusion loop [37,39]. Furthermore, a
recent study showed that non-FccR binding variants of fusion
loop-specific MAbs can be used to therapeutically prevent
enhancement by anti-DENV-immune mouse and human sera
which contain a mixture of E- and prM-specific antibodies [40].
Therefore, it was conceivable that our competition ADE assay
with prM-binding Fab fragments not only blocked the binding of
prM-specific antibodies, but also interfered with fusion loop-
binding antibodies. However, we did not observe significant
competition between the prM Fab fragments and whole MAbs
binding to fusion loop and other E protein epitopes. We conclude
that both fusion loop- and prM-binding antibodies in immune sera
may independently contribute to ADE.
The prM protein is proteolytically cleaved by the host enzyme,
furin, during maturation of DENV in the Golgi apparatus.
Therefore, virus binding and enhancement of infection by prM-
specific antibodies is restricted to the prM-containing virion
particles that are either immature or partially immature. The cell
culture production of DENV yields viral particles with a range of
maturity, consisting of fully mature, partially mature and fully
immature virions in the same virus mix [41]. Published work has
shown that prM-antibodies can even facilitate entry and produc-
tive infection of fully immature virion particles [10]. However, the
maturity of DENV particles produced in humans during a natural
infection is unknown. Therefore, the role of prM-binding
antibodies in enhancement or neutralization during a natural
infection is still unclear.
Viral epitopes recognized by enhancing and neutralizing
antibodies appear to be different both in location and complexity.
Several studies have identified the hinge region between domains I
and II of the E protein as the target of type-specific neutralizing
antibodies in human immune sera [31,42–44]. The neutralizing
antibodies bind to quaternary epitopes that only form after virus
assembly. In contrast, the enhancing epitopes appear to be simpler
in structure because they are preserved on soluble, recombinant
forms of E and prM proteins. Nevertheless, additional consider-
ations such as virus maturation state and the differential surface
exposure of epitopes in virus versus recombinant proteins need to
Figure 6. DENV E-specific antibodies in human serum are partially responsible for ADE of heterotypic DENV infections in AG129
mice. A) Two primary DENV3-immune sera were depleted of cross-reactive DENV rE-specific antibodies, transferred to AG129 mice 24 hours prior to
administration of 26105 pfu of DENV2 D2S10 virus, and assessed for percent survival. Data are pooled from 5 independent experiments using two
different primary DENV3-immune human sera (i.e. DT118 and DT105). **rE-depleted DENV3-immune serum data were significantly different from the
control-depleted DENV3-immune serum data (p = 0.0098).
doi:10.1371/journal.ppat.1004386.g006
Human Antibody Enhancement of Dengue Virus
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be considered when extrapolating from these model systems to
human infections.
Three main human FccRs (FccRI, FccRIIa and FccRIIb) have
been shown to play roles in ADE of DENV in host cells [45–47].
Although both human FccRI and FccRIIa are activating Fcc
receptors, only FccRIIa contains an internal ITAM motif. The
low-affinity FccRIIb is an inhibitory receptor due to the presence
of an ITIM motif [48]. Both FccRI and FccRIIa facilitate the
uptake of IgG-bound virus immune complexes into the host cell,
while cross-linking of FccRIIb with DENV-bound IgG inhibits
uptake of these immune complexes at high antibody concentra-
tions [47]. K562 cells contain the low affinity FccRIIa, but lack
both the high affinity FccRI and the inhibitory FccRIIb [45].
However, unlike FccRI, FccRIIa is more widely expressed in
immune cells, binds all four subclasses of IgG, is more efficient at
the uptake of IgG-bound DENV immune complexes, and has a
polymorphism in humans that is correlated with greater risk for
severe dengue disease [46,49–51]. Therefore, although the
absence of FccRIIb in K562 cells is a valid concern, the absence
of FccRI may not significantly affect the observed data.
The present study demonstrates that a subpopulation of DENV-
specific antibodies in human immune sera were responsible for
ADE in cell culture and in a mouse model of severe dengue
disease. These studies further establish the AG129 mice as a good
model to study ADE. AG129 mice contain the full repertoire of
mouse Fcc receptors, which are capable of binding human IgG.
Our demonstration with model systems in vitro and in vivo that
DENV serotype cross-reactive antibodies in human immune sera
are responsible for enhanced replication and disease is consistent
with the ADE hypothesis proposed for severe dengue in people.
Methods
Viruses and Cell Lines
All in vitro assays were conducted with the DENV WHO
reference strains, i.e., DENV1 West Pac 74, DENV2 S-16803,
Figure 7. prM-specific and rE-specific cross-reactive antibodies together make up the entire population of enhancing antibodies in
DENV-immune human sera. A) DENV1 neutralization by Fab 1B22 (anti-prM), Fab 2K2 (anti-prM), Fab 2D22 (DENV2-specific, negative control), and
MAb 1C19.2 (DENV1-neutralizing, positive control) in U937-DC-SIGN cells. B) Competition ADE assay in K562 cells of Fab fragments with primary
DENV3-immune serum (at peak enhancement concentration) using DENV1. Competition ADE assay of Fab fragments with rE-specific antibody-
depleted DENV3-immune sera, DT118 (C) and DT105 (D) using DENV1 (at peak enhancement concentration) in K562 cells. ****Control depleted
curves significantly different from control-depleted with 1B22 & 2K2 Fab (p,0.0001), rE-depleted (p,0.0001), and rE-depleted with 1B22 & 2K2 Fab
(p,0.0001) by nonparametric ANOVA test.
doi:10.1371/journal.ppat.1004386.g007
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DENV3 CH54389 and DENV4 TVP-360, which were initially
obtained from Dr. Robert Putnak (Walter Reed Army Institute of
Research, Silver Spring, MD). All in vivo assays in the AG129
mice were conducted using the mouse-adapted DENV2 D2S10
strain, which has two defined mutations in the E protein that result
in reduced viral clearance [24,52]. All viruses were grown as
described previously using the Aedes albopictus mosquito cell line
C6/36 [53]. All viruses for antigen purification were grown in the
African green monkey kidney epithelial cell line, Vero. In vitro
ADE and neutralization assays were performed using human
erythromyeloblastoid leukemia K562 cells and DC-SIGN-express-
ing U937 cells (U937-DC-SIGN), respectively. K562 cell lines
were obtained from ATCC, while U937-DC-SIGN were kindly
provided by the laboratory of Dr. Mark Heise at the University of
North Carolina, Chapel Hill.
Human Sera and Fab Fragments
Ethics statement. Blood donations were obtained from
individuals who had traveled to dengue-endemic regions and
experienced a primary DENV1, -2, -3, or -4 infection. These
human samples were obtained with informed consent approxi-
mately 2 to 10 years after DENV infection. All blood donations
were collected in compliance with the Institutional Review Board
of the University of North Carolina at Chapel Hill. Written
informed consent was obtained from all subjects before participa-
tion in the study. All samples were coded and analyzed
anonymously. At least four DENV2-immune sera and four
DENV3-immune sera were tested. DT105 and DT118 are late
convalescent human sera from past primary DENV3 infections,
and have been described previously [31].
The human MAbs 1F4 (DENV1-specific, EDI-EDII hinge
binding), 2D22 (DENV2-specific, EDI-DII hinge binding), 1C19.2
(cross-reactive, EDIII-binding), 1B22 (cross-reactive, prM-binding)
and 2K2 (cross-reactive, prM-binding) were generated in collab-
oration with Dr. Scott Smith in the laboratory of Dr. James Crowe
(Vanderbilt University) [30]. The Fab fragments of 1F4, 2D22,
1C19.2, 1B22 and 2K2 were generated through enzymatic papain
digestion of the respective MAbs. Neutralization and binding
properties of all human MAbs used in present study are displayed
in Table S1.
Depletion of Virus-Specific Antibodies from Human Sera
Human sera were depleted of virus-specific antibodies as
previously described [31]. Briefly, DENV was grown in Vero
cells and purified using ultracentrifugation, sucrose cushion and
Opti-prep gradients as described previously [31,53]. The highly
purified DENV was then passively adsorbed to polystyrene beads
(4.5 mm) and incubated with human sera at 37uC to remove the
appropriate DENV-specific antibodies. Control depletion entailed
incubation of serum with polystyrene beads coated with BSA.
Successful depletion was assessed using a virus-binding ELISA.
Depletion of rE-Specific Antibodies from Human Sera
Human sera were depleted of rE-binding antibodies as
previously described [31]. Briefly, purified recombinant E proteins
(soluble domain) from all four DENV serotypes were purchased
from Hawaii Biotech, Inc. Purified rE was covalently conjugated
to cyanogen bromide (CNBr)-activated beads using amine
chemistry. We have previously demonstrated that the major
antibody-binding epitopes are preserved on rE after covalent
attachment to CNBr-activated beads [31]. The rE-conjugated
beads were then incubated with human sera at 37uC to remove
rE-specific antibodies. Control depletion consisted of depleting
serum with CNBr-activated beads that were conjugated to BSA.
Successful removal of all cross-reactive rE-specific antibodies was
confirmed using a rE-binding ELISA.
ELISA Binding Assays
Binding of depleted human sera to purified DENV or rE
protein was measured using ELISA binding assays as previously
described [31]. Briefly, DENV virions or rE proteins were either
directly coated or captured by the anti-E protein mouse Mab 4G2,
blocked with 1% normal goat serum (Gibco Life Technologies,
USA), and incubated with human serum diluted 1:20, and binding
was detected with an alkaline phosphatase-conjugated anti-human
secondary antibody.
The above protocol was also followed for competition binding
ELISA assays with the difference that the Fab fragments, 1F4 or
1B22 and 2K2, were added to serially diluted (0.0005–8.0 mg/ml)
mouse MAbs prior to incubation with purified DENV2 coated on
ELISA plates. The mouse MAbs used were E protein fusion loop-
binding (4G2 and MAb 30), EDIII-binding (12C1) or prM-
binding (2H2). Fab fragments were used at 1.0 mg/ml for this
competition assay.
Quantification of Anti-fusion Loop Antibodies Using
Wild-Type and Mutant VLPs
DENV fusion loop-binding antibodies in human polyclonal
serum were assessed using wild-type (WT) DENV1 (produced by
pCB-D1 construct) and fusion loop mutant (W101A and F108A)
VLPs as described previously [35,54]. Briefly, WT and mutant
VLPs were captured in a 96-well plate coated with anti-DENV1
rabbit anti-serum. The wells were incubated with a two-fold
dilution series of the human immune sera, followed by incubation
with anti-human IgG conjugated to horseradish-peroxidase, then
TMB substrate and finally stop solution. The percentage of fusion
loop-binding antibodies was calculated using the formula: % anti-
fusion loop antibodies = [1-endpoint titer to mutant VLPs/
endpoint titer to WT VLPs]6100% [35,54].
U937-DC-SIGN Neutralization Assay
The flow cytometry-based DENV neutralization assay was
conducted as described previously [31]. Briefly, human serum was
serially diluted and incubated with DENV for 1 hour at 37uC
under 5% CO2. Virus-antibody mixture was then added to U937-
DC-SIGN cells for 2 hours at 37uC, after which cells were washed
2 times with fresh medium, and then incubated for 22 hours.
Twenty-four hours post-infection, the cells were washed with fresh
medium, fixed with 4% paraformaldehyde, and stained with 2H2
antibody conjugated to Alexa-488, and the percentage of infected
cells was measured by flow cytometry.
ADE Assay in K562 Cells
In vitro ADE assays were conducted in K562 cells as previously
described [55]. Human sera were diluted 2-fold starting from 1:20,
then incubated for 1 hour at 37uC with DENV at an MOI of 1.0.
Approximately 56104 cells were added to each well containing
virus-antibody mixtures and then incubated for 2 hours at 37uC,
after which cells were washed 26 with fresh medium and
incubated at 37uC for another 22 hours. Cells were fixed 24 hours
post-infection, stained for DENV E protein using MAb 2H2 (anti-
prM) conjugated to Alexa-488 and analyzed by flow cytometry to
measure percent infection. The competition ADE assays were
conducted similarly, except for the difference that the Fab
fragments were serially diluted and combined with DENV3-
immune primary sera (at peak enhancing concentration) prior to
incubation with DENV1 for 1 hour.
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ADE Assay in AG129 Mice
In vivo ADE assays in AG129 mice were conducted at UC
Berkeley in the Animal Facility in accordance with Animal Care
and Use Committee Guidelines as previously described [55].
AG129 mice were administered DENV-immune human sera or
normal human serum (NHS) intraperitoneally in a final volume of
200 ml, approximately 24 hours prior to intravenous administra-
tion of a sub-lethal 26105 pfu dose of DENV2 D2S10. Mice were
then observed over a 10-day period or until euthanized and scored
for morbidity and mortality using a standardized 5-point system
[56].
Statistical Analysis
Statistical analysis of Kaplan-Meier survival blots was per-
formed using the Log-rank (Mantel-Cox) test. Students t-test was
used for the in vitro ELISA virus-binding, rE-binding experiments,
and fusion loop antibody quantification experiments. The
nonparametric ANOVA test was used for several ADE experi-
ments.
Supporting Information
Figure S1 prM-specific Fab fragments compete with the
binding of other prM-specific MAbs, but not E protein
fusion loop or EDIII-binding MAbs. Competition binding
ELISA assays were conducted with purified DENV2 virus. The
binding of fusion loop-specific mouse MAbs, 4G2 (A) and MAb 30
(B), EDIII-specific mouse MAb, 12C1 (C), and prM-binding
mouse MAb, 2H2 (D), were competed using either no Fab,
DENV1-specific Fab 1F4, or prM-specific Fabs, 1B22 and 2K2.
MAbs were titrated down and Fabs were added for competition at
a concentration of 1 mg/ml.
(DOCX)
Table S1 DENV binding and neutralization profiles of
human MAbs used in the present study.
(DOCX)
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